Clinical Relevance of Oncogenic Driver Mutations Identified in Endometrial Carcinoma

Takafumi Watanabe (✉ t-wata@fmu.ac.jp)  
Fukushima Medical University School of Medicine  https://orcid.org/0000-0001-6974-0312

Hideaki Nanamiya  
Fukushima Medical University School of medicine

Manabu Kojima  
Fukushima Medical University School of Medicine

Shinji Nomura  
Fukushima Medical University School of Medicine

Shigenori Furukawa  
Fukushima Medical University School of medicine

Shu Soeda  
Fukushima Medical University School of Medicine

Daisuke Tanaka  
Fukushima medical University School of Medicine

Takao Isogai  
Fukushima Medical University school of Medicine

Jun-ichi Imai  
Fukushima Medical University School of Medicine

Shinya Watanabe  
Fukushima Medical university School of Medicine

Keiya Fujimori  
Fukushima Medical University School of Medicine

Research article

Keywords: Endometrial carcinoma, Somatic mutations, Clinical molecular genetics, Prognostic biomarker

DOI: https://doi.org/10.21203/rs.3.rs-56812/v1

License: ☇ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

**Background:** Endometrial carcinoma is a clinically heterogeneous disease characterized by a number of different histological subtypes, and its heterogeneity may be involved in the accumulation of multiple genetic alterations. The aim of this work is to investigate a comprehensive mutational profile of endometrial carcinoma tumors, and examine the correlations with somatic mutations and clinicopathological features or survival in endometrial carcinoma patients.

**Methods:** A total of 100 surgical tumors were obtained from endometrial carcinoma patients who had undergone surgery at Fukushima Medical University Hospital between 2013 and 2017. Genomic DNA samples extracted from fresh-frozen tissues were analyzed using the Ion AmpliSeq Cancer Hotspot Panel v2 Kit covering 50 tumor-related genes.

**Results:** Validated mutations were detected in 91 of the 100 tumors (91%) and identified in eight of the most frequently mutated genes, namely *PTEN* (57%), *PIK3CA* (51%) and *TP53* (30%) *KRAS* (23%), *CTNNB1* (21%), *FBFR2* (13%), *FBXW7* (10%) and *RB1* (9%). *PTEN* mutations correlated with young age (< 60), early-stage, endometrioid histology, non-recurrence and better overall survival. *CTNNB1* mutations correlated with young age, endometrioid histology and better overall survival. On the other hands, *TP53* mutations correlated with late-stage, non-endometrioid histology, high-grade, recurrence and worse overall survival. *FBXW7* mutations correlated with late-stage, vascular invasion and lymph node metastasis. *FGFR2* mutations correlated with deep (≥ 1/2) myometrial invasion. No statistically significant associations were found between clinicopathological characteristics or overall survival and *PIK3CA*, *KRAS* or *RB1* mutations were found.

**Conclusion:** Our study demonstrated that mutations in *PTEN* and *CTNNB1* could be predictive biomarkers for favorable outcome, while mutations in *TP53*, *FBXW7* and *FGFR2* could be those for adverse outcome. Our comprehensive mutational profile is useful for understanding and evaluating the molecular characteristics of endometrial carcinoma patients, and will lead to the establishment of novel treatment strategies that improve the survival of patients with endometrial carcinoma in the future.

Introduction

Endometrial carcinoma (EC) is the most frequent malignancy of the female genital tract, and the seventh most commonly occurring cancer in women worldwide, as of 2018 [1]. EC often produces symptoms, such as postmenopausal or abnormal genital bleeding, at a relatively early-stage, so the disease is generally diagnosed early. Although more than 75% of EC patients are stage I at the time of diagnosis, and the 5-year overall survival (OS) rate for women with early-stage EC exceeds 80%, 10–15% of all tumors have a recurrence [1, 2]. The stage, histological type, tumor grade, myometrial invasion (MI), vascular invasion (VI) and lymph node metastasis (LNM) at the time of treatment are defined as independent prognostic factors in patients with EC by the International Federation of Obstetrics and Gynecology (FIGO) [3]. However, to explain EC heterogeneity with these clinicopathological factors alone
is impossible [4]. Therefore, identification of new predictive markers for a high-risk phenotype would be very useful for selection of the most efficient therapies and the development of novel treatment modalities.

Recently, comprehensive molecular profiling of cancer using next-generation sequencing (NGS) approaches is increasingly used in oncology for diagnostic and therapeutic management decisions. Cancer-specific mutations, including single-nucleotide alterations and small insertions or deletions, are known to affect key driver genes early during tumorigenesis [5]. There are two types of EC: Type I EC (80–90%) characterized by an excess of estrogen is typically endometrioid endometrial carcinoma (EEC) with low-grade and has a favorable outcome. In contrast, type II EC (10–20%) is usually non-endometrioid endometrial carcinoma (NEEC) (serous carcinoma, clear cell carcinoma and malignant mixed mullerian tumor) with high-grade tumors and poor prognosis. In previous reports, frequent somatic mutations of PTEN, CTNNB1, PIK3CA, ARID1A and KRAS in type I EC, as well as those of TP53 genes in type II EC, have been identified using whole exome and genome sequencing analysis [6, 7]. Although several studies have reported associations between each somatic mutation and clinicopathological characteristics of EC [8–10], there have been few studies focusing on a comprehensive somatic mutation analysis [6]. In the present study, we performed a comprehensive mutational profile in EC patients using a cancer panel, and examined whether somatic mutation status is associated with risk factors or survival.

**Materials And Methods**

**Clinical samples**

A total of 100 surgical tumors were obtained from EC patients who had undergone surgery at Fukushima Medical University Hospital between August 2013 and December 2017. The clinicopathological data for age, staging (FIGO 2008), histology, tumor grade (EEC), MI, VI, LNM, and recurrence was collected by operative reports, clinical notes and pathological reports. Histology was divided into EEC and NEEC. Adjuvant therapy was determined according to the physician's treatment strategy. The study design was approved by the ethics committee of Fukushima Medical University (No. 1953), and informed consent was obtained from all participants. All analyses were performed in accordance with the relevant guidelines and regulations.

**Dna Extraction**

Isolation and purification of genomic DNAs after extraction of RNAs from 100 fresh- frozen tumor samples were performed using ISOGEN reagent (Nippongene, Tokyo, Japan), according to the manufacturer's instructions. The concentration and quality of each DNA sample were assessed using NanoDrop One (ThermoFisher Scientific, Waltham, MA, USA).

**Somatic Mutation Detection**
The Ion Ampliseq Cancer Hotspot Panel v2 on the Ion Torrent platform was used to detect 2790 mutations in 50 oncogenes and tumor suppressor genes [11, 12]. In brief, 10 ng of genomic DNAs extracted from 100 frozen tumor samples were used to construct barcoded DNA libraries utilizing an Ion Ampliseq Library Kit 2.0 (Thermo Fisher Scientific). The obtained libraries were optimized using an Ion Library Equalizer Kit (Thermo Fisher Scientific), and then sequenced using an Ion Personal Genome Machine or Ion S5XL platform (Thermo Fisher Scientific). The sequencing reads were aligned to the reference genome build hg19, GRCh37, and converted into BAM files using Ion Torrent Suite software (Thermo Fisher Scientific). Sequence variants were then called using Ion Reporter 5.0 (Thermo Fisher Scientific), according to the manufacturer’s instructions. The average sequencing depth reached at least 1500-fold per sample.

Statistical analysis.

The associations between somatic mutations and categorical variables, as well as between mutation rate or frequency and categorical variables, were evaluated using the chi-squared test or Mann-Whitney U Test. OS was evaluated as clinical outcomes. Survival distributions were calculated according to the Kaplan-Meier method, and statistical significance was determined using the log-rank test. Values of $P < 0.05$ were considered statistically significant. Statistical analysis of data was performed using SPSS version 25 software (SPSS, Inc., Chicago, IL, USA).

Results

Clinicopathological characteristics.

The clinicopathological characteristics of all the patients are shown in Table 1. A total of 100 EC patients who had been treated with surgery were enrolled in this study. The median age at diagnosis was 62.5 years (range, 32–89 years), and 62 (62%) of the patients with high recurrence risk or advanced stage underwent platinum-based chemotherapy postoperatively. Among the 100 tumors, 82 were EEC and 18 were NEEC (nine serous, six clear cell, two undifferentiated and one mixed carcinoma). After a median follow-up of 37 months (range, 1–76 months), 78 (78%) patients were alive without clinical evidence of tumor. Recurrence was identified during the follow-up period in 22 (22%) patients: six (6%) patients were alive with disease; sixteen (16%) patients died due to their tumor between postoperative months 1 and 42 (median, 7.5 months).

| Table 1 |
| Clinicopathological characteristics of patients with endometrial cancer. |

Spectrum and frequency of mutations in EC.
In order to explore the mutations of spectrum and frequency in EC, 100 fresh-frozen tumors were analyzed. Figure 1 shows a summary of somatically altered genes that are recurrently mutated. Validated mutations were detected in 91 of the 100 tumors (91%), and 77 of the 100 tumors (77%) harbored concurrent mutations in two or more genes. Of 50 tumor-related genes, 37 were observed in EC tumors. Mutations were most frequently detected in \textit{PTEN} (57%), \textit{PIK3CA} (51%) and \textit{TP53} (30%) (Fig. 1). \textit{KRAS}, \textit{CTNNB1}, \textit{FBFR2}, \textit{FBXW7} and \textit{RB1} mutations were relatively frequent, with respectively 23%, 21%, 13%, 10% and 9%, followed by \textit{APC} (6%), \textit{SMARCB1} (5%), \textit{AKT1}, \textit{ATM}, \textit{BRAF}, \textit{ERBB2} and \textit{MET} (4%) \textit{ERBB4}, \textit{GNAS}, \textit{KIT}, \textit{SMAD4}, \textit{SMO} and \textit{STK11} (3%) \textit{ABL}, \textit{FGFR3}, \textit{HNF1A}, \textit{KDR} and \textit{NRAS} (2%) \textit{EGFR}, \textit{CDH1}, \textit{CDKN2A}, \textit{EGFR1}, \textit{GNAQ}, \textit{IDH1}, \textit{JAK2}, \textit{MLH1}, \textit{MPL}, \textit{NOTCH1} and \textit{VHL} (1%) (Fig. 1). A total of 284 (mean, 2.84) mutations were detected; 212 (74.6%) missense mutations, 39 (13.7%) nonsense mutations, 26 (9.2%) frameshift indels and seven (2.5%) non-frameshift indels (Fig. 1).

We examined the differences in mutation rates between EEC and NEEC using a chi-squared test. The mutation rate was significantly higher in the EEC (93.9%, 77/82) than in the NEEC (77.7%, 14/18) (P = 0.03). The association between mutation frequencies and clinicopathological features was investigated by the Mann-Whitney U Test. Age, histology and tumor grade were significantly correlated with mutation frequencies (Fig. 2a, b, c). On the other hand, there were no significant associations between stage, MI, VI, LNM, or recurrence and mutation frequencies (Supplementary Table 1).

**Relationships Between Mutation Status And Clinicopathological Characteristics**

Table 2 shows a summary of the associations between eight most frequently mutated genes (\textit{PTEN}, \textit{PIK3CA}, \textit{TP53}, \textit{KRAS}, \textit{CTNNB1}, \textit{FBFR2}, \textit{FBXW7} and \textit{RB}) and clinicopathological characteristics in EC patients. Patients with \textit{PTEN} and \textit{CTNNB1} mutations had a significantly younger age (< 60) than those without these mutations (P = 0.003 and P = 0.006, respectively). The \textit{TP53} and \textit{FBXW7} mutations were significantly observed in late-stage EC (P = 0.017 and P = 0.023, respectively), whereas \textit{PTEN} mutation was significantly more common in early-stage EC (P = 0.007). \textit{TP53} mutation was significantly more common in NEEC tumors (P = 0.001), whereas the \textit{PTEN} and \textit{CTNNB1} mutations were significantly more common in EEC tumors (P = 0.001 and P = 0.02, respectively). \textit{TP53} mutations correlated with high-grade tumor (P = 0.0001). \textit{FGFR2} mutations were significantly observed in deep (≥ 1/2) MI (P = 0.016). On the other hand, the association of \textit{CTNNB1} mutation with superficial (< 1/2) MI was marginally significant (P = 0.071). \textit{FBXW7} mutations significantly correlated with VI (P = 0.001). The association between \textit{TP53} mutation and VI was also marginally significant (P = 0.088). In contrast, the association between \textit{CTNNB1} mutation and non-VI was marginally significant (P = 0.064). \textit{FBXW7} mutations significantly correlated with LNM (P = 0.029). The association of \textit{TP53} mutation with LNM was also marginally significant (P = 0.056). On the other hand, the association of \textit{PTEN} mutation with non-LNM was also marginally significant (P = 0.08). \textit{TP53} mutation was significantly associated with recurrence (P = 0.004), whereas \textit{PTEN} mutation was significantly associated with non-recurrence (P = 0.001).
Correlations Of Mutation Status With Clinical Survival

The relationship between the eight most frequently mutated genes (PTEN, PIK3CA, TP53, KRAS, CTNNB1, FGFR2, FBXW7, and RB) and clinical survival was analyzed by log-rank test. The Kaplan-Meier curves for PTEN, TP53 and CTNNB1 mutations in EC patients are shown in Fig. 3. Patients with PTEN and/or CTNNB1 mutations had a significantly better OS than those without these mutations (P = 0.019 and P = 0.033, respectively) (Fig. 3a, b), whereas those with TP53 mutation had a significantly worse OS (P = 0.001) (Fig. 3c). However, PIK3CA, KRAS, FBFR2, FBXW7 and RB1 mutations had no significant associations with OS.

Discussion

Our findings showed a very high rate (91%) of a potential oncogenic driver or drug targetable mutations in EC patients. Validated mutations have been also reported in 78–94% of EC patients using a cancer panel [13, 14], and EC is known as a tumor with a high frequency of mutated genes. The comprehensive genomic analysis by The Cancer Genome Atlas (TCGA) resulted in the molecular classification of EC into four distinct subgroups [6]: the POLE group has an exceedingly high mutation rate in conjunction with somatic mutations in the exonuclease domain of POLE; The microsatellite instability (MSI) group has a high mutation rate and is a hallmark of a defective mismatch repair system because of hypermethylation of the MLH1 promoter or a germline mutation in one of the mismatch repair genes; the copy number (CN)-low group has a low mutation rate and most of the microsatellite stable EEC; and the CN-high group has a low mutation rate and consists serous carcinoma with extensive high-level CN alterations and frequent somatic mutations in TP53. POLE, MSI and CN-low are almost exclusively of endometrioid morphology, whereas serous carcinoma contained in NEEC is almost exclusively in the CN-high group. POLE and MSI tumors have a high mutation frequency, which is approximately 100-fold and 6-fold greater than that seen in CN-low or CN-high tumors, respectively. POLE-mutated tumors are frequently of high-grade endometrioid histology. In the present study, the mutated frequencies were significantly higher in high-grade EEC tumors than in low-grade EEC tumors. Moreover, EEC tumors had a significantly higher mutation frequency than NEEC. Although we did not examine integrated POLE mutation, or perform MSI assay or CN analysis, our findings were consistent with those of TCGA.
We here investigated the associations between the eight most frequently mutated genes and prognostic risk factors or survival in EC patients. *PTEN* is identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. *PTEN* was found to be mutated at the highest frequency in the present study. In particular, the rate of *PTEN* mutations in the EEC tumors was significantly higher than that in the NEEC tumors. The difference in the prevalence of *PTEN* mutation between EEC and NEEC was similar to that in previous studies [6, 15]. Since *PTEN* mutation is present in a relatively large proportion of atypical endometrial hyperplasia, which is known as a precancerous lesion, it may be considered an early event in the pathogenesis of EEC tumor [16, 17]. *PTEN* mutation is frequently observed in type I EC and is correlated with young age, early-stage, endometrioid subtype, low-grade and favorable prognosis as suggested by previous studies [18, 19], similar to our results.

*PIK3CA* is one of the most commonly mutated genes in solid cancers, and the majority of *PIK3CA* mutations cluster in hotspot regions in exon 9 (the helical domain) and exon 20 (the kinase domain) [20]. The *PIK3CA* mutation has been frequently detected in not only EEC but also NEEC [21, 22] as in the present study. As for survival, no significant association has been reported between *PIK3CA* mutations and disease-free survival in 94 EC patients [10]. On the other hand, associations have been reported between *PIK3CA* missense mutation and unfavorable outcome in grade 3 EEC tumors, and between *PIK3CA* exon 9 mutations and reduced survival in EC patients [23, 24]. In the current study, there were no significant associations between the *PIK3CA* mutation and any clinicopathological features or survival. A consensus on mechanism by which *PIK3CA* affects EC prognosis has yet to be achieved. Evaluation of the relationship between *PIK3CA* mutation and risk factors requires individualization with large samples.

Tumor suppressor p53 plays an important role in the preservation of genomic stability from various damages through the regulation of cell-cycle checkpoints, DNA repair, senescence and apoptosis, and *TP53* is one of the most frequent alterations in human cancer. The frequency of somatic mutation in *TP53* was 30% in our study. In particular, *TP53* mutations in EEC were significantly fewer than those in NEEC, and the proportion was similar to that of a previous study [25]. In addition, the associations of *TP53* mutation with late-stage, high grade, and poor OS were statistically significant. Furthermore, *TP53* mutations had marginally significant associations with LNM. The CN-high category represents serous-like EC, and mostly incorporates *TP53* mutation, indicating a poor prognosis [6]. These results suggest that somatic mutation in *TP53* can be the best predictive biomarker for poor prognosis in EC patients, and has the opposite characteristic of *PTEN* mutation.

The *KRAS* proto-oncogene regulates cell division as a result of its ability to relay external signals to the cell nucleus. Activating mutations in the *KRAS* gene promotes down-regulation of MAPK or PI3K/AKT, which further results in excessive cell proliferation and subsequent carcinogenesis. *KRAS* mutation is present in up to 25% of all human tumors, and this is one of the most frequently activated oncogenes [26]. *KRAS* mutations in EC have been mostly associated with type I estrogen-dependent EC, and their frequency is estimated around 10–30% [27–29]. Although *KRAS* mutation was also found in 24% (20/82) of the EEC tumors, there was no significant difference between EEC and NEEC in the present study. *KRAS* mutation is a relatively common event in endometrial carcinogenesis, but its prognostic value is limited.
Sideris et al reported that a consensus on the exact way that KRAS overall affects EC prognosis has yet to be achieved [30]. In the present study, no significant correlation between KRAS mutation and OS was observed, so the prognostic significance of KRAS mutation remains controversial.

CTNNB1 is a gene involved in the Wnt signaling pathway, which regulates cell growth, motility and differentiation. CTNNB1 mutation is the activation of the Wnt signaling pathway, and has been specifically shown to be associated with carcinogenesis in many types of tumors [31]. Since CTNNB1 mutations seemingly occur in atypical endometrial hyperplasia, CTNNB1 mutation plays a critical role in the initiation and early progression of EEC tumors [32]. Other studies identified an increase in CTNNB1 mutations in EEC compared to NEEC [33, 34], and no CTNNB1 mutation was observed in the NEEC tumors in the present study. CTNNB1 mutation was detected in 25.6% (21/82) of EEC tumors, which was a similar frequency to that previously reported in this series [33–35]. We here demonstrated that CTNNB1 mutation was significantly associated with young age, endometrioid subtype and favorable OS, and borderline significantly associated with early-stage, superficial MI and VI. The clinicopathological features of CTNNB1 mutations were similar to those of PTEN mutations; 90% (19/21) of tumors with CTNNB1 mutation also had PTEN mutation. These data suggest that CTNNB1 mutation may be a favorable prognostic biomarker in addition to PTEN mutation. However, recent studies have described significant associations between CTNNB1 mutations and poor outcome among low-risk EEC patients, suggesting prognostic significance of CTNNB1 mutation among low-risk EEC tumors needs to be carefully interpreted.

FGFR2 is one of the receptors for fibroblast growth factor, and has been shown to be activated in a number of cancers through a variety of mechanisms, including gene amplification, translocations, and point mutations [39]. Some studies subsequently reported a FGFR2 mutation frequency of 10–16% in EC tumors [34, 40, 41], and said frequency in the current study was 13%. In the present study, there was a significant association between FGFR2 mutation and deep MI. To the best of our knowledge, these findings have not yet been reported. Jeske et al. suggested that clinical trials testing the efficacy of FGFR inhibitors in the adjuvant setting to prevent recurrence and death are warranted because FGFR2 mutations are associated with poor outcomes in EEC [41]. Although we did not investigate the relationships between FGFR2 mutations and OS, FGFR2 mutations may contribute to a poor prognosis for EC with MI.

FBXW7 is a critical tumor suppressor that regulates proteasome-mediated degradation of various oncoproteins, such as cyclin E, c-Myc, Mcl-1, mTOR, Jun, Notch and AURKA in human cancer [42]. FBXW7 mutations have been reported in several types of human cancers and found in 2.54% across all human tumors, according to COSMIC database meta-analyses [43]. Previous studies subsequently reported an FBXW7 mutation frequency of 2–16% in EC tumors [28, 44], and said frequency in the current study was 10%. In particular, FBXW7 mutation is observed in 20–30% of serous EC [6, 21, 22] and was also found in 30% (3/10) in the present study (data not shown). The results of the present study showed that FBXW7 mutation correlated with late-stage, VI and LNM. In particular, the relationship between FBXW7 mutation and VI in EC was a novel finding. Loss of FBXW7 function caused by mutation resulted in high
Brg1 expression, and was consequently associated with VI, LNM and distant metastasis in gastric cancer [45]. Although there was no significant association between *FBXW7* mutation and OS in the current study, *FBXW7* mutation may be a predictive biomarker for poor prognosis.

The *RB1* gene, located on chromosome 13, is a well-known tumor suppressor gene that was discovered in genetic studies of hereditary retinoblastoma [46]. Defects in this gene are a cause of childhood cancer, bladder cancer, and osteogenic sarcoma. Loss of heterozygosity was reported in 18% of *RB* genes in EC and pRB downregulation was consistent with loss of heterozygosity [47]. Although *RB* mutation was detected in 9% of EC patients, no significant association was observed between clinicopathological features or survival and *RB* mutation. Our data indicate that inactivation of *RB1* was not a useful biomarker for EC.

However, the present study must be interpreted with caution, and a few limitations should be kept in mind. Said limitations include the small sample size, heterogeneity of histology or treatment within the cohort, and short follow-up period as they may have affected the association between somatic mutations and clinical outcomes. Another limitation is that our analysis relied on sequencing with a cancer hotspot panel, and only explained a portion of the total genetic alterations. The NGS platform used in this study detected only single nucleotide variants, and thus it was impossible to detect copy number variants and MSI status. Therefore, a large number of samples with long-term follow-up need to be prospectively analyzed using whole exome or genome sequencing that can detect single number variants, copy number variants and MSI status. Furthermore, other novel genetic or epigenetic alterations should be explored as well.

**Conclusion**

We demonstrated that our comprehensive NGS analysis using a cancer panel was feasible for mutational profiling of EC tumors. Although the mutated gene significance for clinical outcomes in EC patients was similar to that found in previous work, new findings, the correlations between *FGFR2* mutation and deep MI and between *FBXW7* mutation and VI, were revealed. Our current study suggests that EC patients can benefit from molecular profiling with predictable prognostic factors and select systemic adjuvant chemotherapy in combination with specific targeted therapies. We believe that this work is useful for understanding and evaluating the molecular characteristics of EC patients, and will lead to the establishment of novel treatment strategies that improve the survival of patients with EC in the future.

**Abbreviations**

EC
Endometrial carcinoma, OS:Overall survival, MI:Myometrial invasion, VI:Vascular invasion, LNM:Lymph node metastasis, FIGO:International Federation of Obstetrics and Gynecology, NGS; Next-generation sequencing, EEC:Endometrioid endometrial carcinoma, NEEC:Non-endometrioid endometrial carcinoma, TCGA:The Cancer Genome Atlas
Declarations

Authors’ contributions

TW, SW and KF conceived and designed the experiments. TW, MK, SN, SF, SS and KF collected samples and clinical data. HN, DT, TI, JI and SW performed molecular profile. TW analyzed the data and wrote the paper.

Funding

The present study was supported by grants for Translational Research Programs from Fukushima Prefecture.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The study protocol was approved by the Ethics Committee of Fukushima Medical University School of Medicine (No. 1953), and informed consent was obtained from all patients. All participants signed informed consent forms.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

References

1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019;144(8):1941–53.

2. Sohaib SA, Houghton SL, Meroni R, Rockall AG, Blake P, Reznek RH. Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. Clin Radiol. 2007;62(1):28–34.

3. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105(2):103–4.

4. Werner HM, Salvesen HB. Current status of molecular biomarkers in endometrial cancer. Curr Oncol Rep. 2014;16(9):403.
5. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458(7239):719–24.

6. Kandoth C, Schultz N, Chenjiack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.

7. Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, Tatebe K, Veneris JL. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 2019;69(4):258–79.

8. Risinger JI, Hayes K, Maxwell GL, Carney ME, Dodge RK, Barrett JC, Berchuck A. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res. 1998;4(12):3005–10.

9. Lee EJ, Kim TJ, Kim DS, Choi CH, Lee JW, Lee JH, Bae DS, Kim BG. p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review. Gynecol Oncol. 2010;116(3):533–8.

10. Dong Y, Yang X, Wong O, Zhang X, Liang Y, Zhang Y, Wong W, Nong L, Liao Q, Li T. PIK3CA mutations in endometrial carcinomas in Chinese women: phosphatidylinositol 3'-kinase pathway alterations might be associated with favorable prognosis. Hum Pathol. 2012;43(8):1197–205.

11. Hodgson A, Amemiya Y, Seth A, Cesari M, Djordjevic B, Parra-Herran C. Genomic abnormalities in invasive endocervical adenocarcinoma correlate with pattern of invasion: biologic and clinical implications. Mod Pathol. 2017(11);30:1633–641.

12. Nemtsova MV, Kalinkin AI, Kuznetsova EB, Bure IV, Alekseeva EA, Bykov II, Khorobrykh TV, Mikhaylenko DS, Tanas AS, Kutsev SI, et al. Clinical relevance of somatic mutations in main driver genes detected in gastric cancer patients by next-generation DNA sequencing. Sci Rep. 2020;10(1):504.

13. Boland GM, Piha-Paul SA, Subbiah V, Routbort M, Herbrich SM, Baggerly K, Patel KP, Brusco L, Horombe C, Naing A, et al. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015;6(24):20099–110.

14. Wang M, Fan W, Ye M, Tian C, Zhao L, Wang J, Han W, Yang W, Gu C, Li M, et al. Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers. Sci Rep. 2018;8(1):8990.

15. McConechy MK, Ding J, Cheang MC, Wiegand K, Senz J, Tone A, Yang W, Prentice L, Tse K, Zeng T, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol. 2012;228(1):20–30.

16. Levine RL, Cargile CB, Blazes MS, van Rees B, Kurman RJ, Ellenson LH. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res. 1998;58(15):3254–58.

17. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, Weng LP, Eng C. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000;92(11):924–30.
18. Sun H, Enomoto T, Fujita M, Wada H, Yoshino K, Ozaki K, Nakamura T, Murata Y. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Am J Clin Pathol. 2001;115(1):32–8.

19. Salvesen HB, Stefansson I, Kretzschmar EI, Gruber P, MacDonald ND, Ryan A, Jacobs IJ, Akslen LA, Das S. Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. Int J Oncol. 2004;25(6):1615–23.

20. Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, Nicoletti F, Stivala F, McCubrey JA, Libra M. PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle. 2009;8(9):1352–8.

21. Kuhn E, Wu RC, Guan B, Wu G, Zhang J, Wang Y, Song L, Yuan X, Wei L, Roden RB, et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst. 2012;104(19):1503–13.

22. Le Gallo M, O'Hara AJ, Rudd ML, Urick ME, Hansen NF, O'Neil NJ, Price JC, Zhang S, England BM, Godwin AK, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet. 2012;44(12):1310–5.

23. McIntyre JB, Nelson GS, Ghatage P, Morris D, Duggan MA, Lee CH, Doll CM, Köbel M. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrioid carcinoma. Gynecol Oncol. 2014;132(1):188–93.

24. Mjos S, Werner HMJ, Birkeland E, Holst F, Berg A, Halle MK, Tangen IL, Kusonmano K, Mauland KK, Oyan AM, et al. PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. Sci Rep. 2017;7(1):10240.

25. Schultheis AM, Martelotto LG, De Filippo MR, Piscuglio S, Ng CK, Hussein YR, Reis-Filho JS, Soslow RA, Weigelt B. TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers. Int J Gynecol Pathol. 2016;35:289–300.

26. Kranenburg O. The KRAS oncogene: past, present, and future. Biochim Biophys Acta. 2005;25(2):81–2. 1756(.

27. Llobet D, Pallares J, Yeramian A, Santacana M, Eritja N, Velasco A, Dolcet X, Matias-Guiu X. Molecular pathology of endometrial carcinoma: Practical aspects from the diagnostic and therapeutic viewpoints. J Clin Pathol. 2009;62(9):777–85.

28. Garcia-Dios DA, Lambrechts D, Coenegrachts L, Vandenput I, Capoen A, Webb PM, Ferguson K, ANECS, Akslen LA, Claes B, Vergote I, et al. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. Gynecol Oncol. 2013;128(2):327–34.

29. Banno K, Yanokura M, Iida M, Masuda K, Aoki D. Carcinogenic mechanisms of endometrial cancer: Involvement of genetics and epigenetics. J Obstet Gynaecol Res. 2014;40(8):1957–67.

30. Sideris M, Emin EI, Abdullah Z, Hanrahan J, Stefatou KM, Sevas V, Emin E, Hollingworth T, Odejinmi F, Papagrigoriadis S, et al. The Role of KRAS in Endometrial Cancer: A Mini-Review. Anticancer Res. 2019;39(2):533–39.
31. Klaus A, Birchmeier W. Wnt signaling and its impact on development and cancer. Nat Rev Cancer. 2008;8(5):387–98.

32. Moreno-Bueno G, Hardisson D, Sarrio D, Sanchez C, Cassia R, Prat J, Herman JG, Esteller M, Matías-Guiu X, Palacios J. Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J Pathol. 2003;199(4):471–8.

33. Machin P, Catasus L, Pons C, Munoz J, Matias-Guiu X, Prat J. CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. Hum Pathol. 2002;33(2):206–12.

34. Byron SA, Gartside M, Powell MA, Wellens CL, Gao F, Mutch DG, Goodfellow PJ, Pollock PM. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS One. 2012;7(2):e30801.

35. Liu Y, Patel L, Mills GB, Lu KH, Sood AK, Ding L, Kucherlapati R, Mardis ER, Levine DA, Shmulevich I, et al. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J Natl Cancer Inst. 2014;106(9):dju245.

36. Kurnit KC, Kim GN, Fellman BM, Urbauer DL, Mills GB, Zhang W, Broadus RR. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence. Mod Pathol. 2017;30(7):1032–41.

37. Myers A, Barry WT, Hirsch MS, Matulonis U, Lee L. Beta-catenin mutations in recurrent FIGO IA grade I endometrioid endometrial cancers. Gynecol Oncol. 2014;134(2):426–27.

38. Stelloo E, Nout RA, Osse EM, Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Nijman HW, Putter H, Bosse T, et al. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. Clin Cancer Res. 2016;22(16):4215–24.

39. Hierro C, Rodon J, Tabernero J. Fibroblast growth factor (FGF) receptor/FGF inhibitors: novel targets and strategies for optimization of response of solid tumors. Semin Oncol. 2015;42(6):801–19.

40. Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H, Mohammadi M, Futreal PA, Stratton MR, et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene. 2007;26(50):7158–62.

41. Jeske YW, Ali S, Byron SA, Gao F, Mannel RS, Ghebre RG, DiSilvestro PA, Lele SB, Pearl ML, Schmidt AP, et al. FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017;145(2):366–73.

42. Yeh CH, Bellon M, Nicot C. FBXW7: a critical tumor suppressor of human cancers. Mol Cancer. 2018;17(1):115.

43. Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, Cole CG, Ward S, Dawson E, Ponting L, et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 2017;45(D1):D777–D83.
44. Spruck CH, Strohmaier H, Sangfelt O, Müller HM, Hubalek M, Müller-Holzner E, Marth C, Widschwendter M, Reed SI. hCDC4 gene mutations in endometrial cancer. Cancer Res. 2002;62(16):4535–9.

45. Huang LY, Zhao J, Chen H, Wan L, Inuzuka H, Guo J, Fu X, Zhai Y, Lu Z, Wang X, et al. SCF<sup>FBW7</sup>-mediated degradation of Brg1 suppresses gastric cancer metastasis. Nat Commun. 2018;9(1):3569.

46. Berry JL, Polski A, Cavenee WK, Dryja TP, Murphree AL, Gallie BL. The RB1 Story: Characterization and Cloning of the First Tumor Suppressor Gene. Genes (Basel). 2019;10(11):879.

47. Semczuk A, Marzec B, Roessner A, Jakowicki JA, Wojcierowski J, Schneider-Stock R. Loss of heterozygosity of the retinoblastoma gene is correlated with the altered pRb expression in human endometrial cancer. Virchows Arch. 2002;441(6):577–83.

**Figures**

**Figure 1**

---

**Histology**

Gene

PTEN
P53C4
TP53
KRAS
CTNNB1
FGFR2
FKRW7
R91
APC
SMARC1
AKT1
ATM
BRAF
ERBB2
MEF
ERBB1
GNAS
KIT
SMAD4
SMO
STK11
AAR
FGFR1
HNF4A
KDR
NRAS
EGFR
CDH1
CDKN2A
EZH2
FGFR1
GNH4
IDH1
JAK2
MLH1
MPL
MOTCH1
VHL

Histology: Endometrioid carcinoma, Non-Endometrioid carcinoma

Mutations: Missense, Nonsense, Frameshift InDel, Non-Frameshift InDel
Summary of the relationships between somatic mutations and histological characteristics of endometrial cancer. All panels are aligned with vertical tracks representing 100 individuals.

Figure 2

Box plot showing differences in mutation frequency between (a) < 60 and ≥ 60 (P = 0.003). (b) EEC and NEEC (P=0.03). (c) Grade 1 + 2 and Grade 3 (P = 0.005) EEC: endometrial endometrioid carcinoma, NEEC: non-endometrial endometrioid carcinoma
Figure 3

The Kaplan-Meier curves of overall survival in patients with endometrial cancer. (a) Patients with and without PTEN mutations (P = 0.019). (b) Patients with and without CTNNB1 mutations (P = 0.033). (c) Patients with and without TP53 mutations (P = 0.001).